Tags : Incidence


G1 Therapeutics’ Cosela (trilaciclib) Receives US FDA’s Approval as the

Shots: The approval is based on three clinical trials involves assessing Trilaciclib +carboplatin/etoposide (+/- atezolizumab) and topotecan CT regimens in patients with ES-SCLC. 90% of all patients with ES-SCLC will receive at least one of these regimens The result show reductions in the incidence and duration of severe neutropenia, positive impact on RBC transfusions and […]Read More